In addition to scoring methods, recommendations included that breast cancer samples for Ki67 testing be processed in line with American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) guidelines for HER2 and hormone receptors, and that they ideally be tested on core needle biopsies since this minimizes fixation problems that can impact analytical validity. Here, MKI67 is linked to breast carcinoma.